Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14results about How to "High transduction efficiency" patented technology

Batch production method of retroviral vector, and vector and application thereof

The invention provides a batch production method of a retroviral vector, which comprises the following steps: constructing a BaEV retrovirus stable packaging cell line, transfecting a common virus preparation cell line with a retroviral vector plasmid comprising a target sequence so as to harvest the retroviral vector capable of producing toxin in a transient conversion manner, and transduction of the BaEV retrovirus stable packaging cell line is carried out by the retrovirus vector, such that the stable BaEV-target sequence retrovirus vector packaging cell line is obtained. The method is low in cost, high in quality and capable of efficiently and industrially preparing the virus on a large scale, compared with instantaneous transfection BaEV lentivirus production, the high-titer virus vector can be generated without multi-plasmid transfection, the manufacturing process is more simplified, the cost is lower, the product quality can be better controlled, and large-scale production can be achieved.
Owner:GUANGDONG JUNHOU BIOMEDICAL CO LTD +1

Method for constructing BaEV envelope stable toxin-producing cell line, and cell line and application thereof

The invention provides a method for constructing a BaEV envelope stable toxin-producing cell line and application of the BaEV envelope stable toxin-producing cell line, and the method comprises the following steps: constructing an HEK293T cell line or a derivative cell line of the HEK293T cell line in which ASCT-1 and ASCT-2 receptor proteins are knocked out at the same time, and then transferring a BaEV envelope into the HEK293T cell line or the derivative cell line of the HEK293T cell line to obtain the BaEV envelope stable toxin-producing cell line. According to the invention, the ASCT-1 / 2 receptor of the HEK293T cell is knocked out for the first time, the problems of BaEV envelope-induced intercellular fusion and syncytial body formation are solved, the cell is not influenced by virus infection any more, and the cell can grow continuously and produce toxin continuously.
Owner:SHENZHEN CELL VALLEY BIOMEDICAL CO LTD +1

Preparation method of retroviral vector with CAR (chimeric antigen receptor) as well as vector and application of retroviral vector

The invention provides a preparation method of a retroviral vector with a CAR (chimeric antigen receptor) as well as the vector and application thereof, the method comprises the preparation method of the retroviral vector with the CAR, the method comprises the following steps: constructing a BaEV retrovirus stable packaging cell line, transfecting a virus with a retroviral vector plasmid with the CAR to prepare a cell line, and screening the cell line to obtain the retroviral vector with the CAR. According to the method, a BaEV retrovirus stable packaging cell line is transduced by the retrovirus vector, so that a stable BaEV-CAR retrovirus vector packaging cell line is obtained. According to the present invention, the efficient transduction of the NK cells, the T cells and other difficult-to-transduction primary immune cells can be achieved under the low MOI, the transduction positive rate can be as high as 90% and can be maintained stable, and the ultrahigh transduction efficiency does not affect the motility and the amplification of the NK cells and the T cells.
Owner:SHENZHEN CELL VALLEY BIOMEDICAL CO LTD +1

BaEV retrovirus vector packaging method and packaging cell line thereof

The invention provides a packaging method of a BaEV retrovirus vector, which comprises the following steps: constructing a BaEV retrovirus stable packaging cell line, transfecting a virus preparation cell line with a retrovirus vector plasmid comprising a target sequence, and harvesting a retrovirus vector for transient conversion toxin production by using the virus preparation cell line which is an HEK293T cell line or a derivative cell line thereof, and mixing with a BaEV retrovirus stable packaging cell line, and promoting the transduction of the BaEV retrovirus stable packaging cell line by the retrovirus vector in a horizontal centrifugation manner. According to the invention, packaging of the BAEV type retrovirus vector carrying the CD19CAR exogenous gene plasmid can be realized, a BAEV type retrovirus vector production cell line is constructed, and the high-titer BAEV type retrovirus vector is produced.
Owner:SHENZHEN CELL VALLEY BIOMEDICAL CO LTD

Bispecific antibodies targeting cd22 and cd19 and chimeric antigen receptors and uses thereof

ActiveCN116217732BHigh transduction efficiencyincrease lethalitySingle-Chain AntibodiesTumor antigen
The application belongs to the technical field of cell engineering, and particularly relates to a bispecific antibody targeting CD22 and CD19, a chimeric antigen receptor thereof and application. In the bispecific antibody, a CD22 light chain and a CD22 heavy chain are connected through a linker 4 to form a CD22 single-chain antibody, and a CD19 light chain and a CD19 heavy chain are connected through a linker 4 to form a CD19 single-chain antibody, which comprises one of the following structures: (1) the CD22 single-chain antibody and the CD19 single-chain antibody are connected through a linker 1 or a liner 2; (2) the two ends of the CD19 single-chain antibody are connected with the CD22 light chain and the CD22 heavy chain through a linker 3, respectively. The chimeric antigen receptor provided by the application can simultaneously target two different tumor antigens, improve the killing of tumor cells, reduce the probability of immune escape, and reduce the tumor recurrence rate after CAR-T treatment.
Owner:CHONGQING PRECISION BIOTECH CO LTD +1

Method for introducing target gene into immune cell

The present invention relates to a method for efficiently expressing a gene of interest in an immune cell, more particularly a natural killer cell, using a viral vector. Under the condition that enzyme or small molecules are not added, a simple step of freezing and unfreezing the natural killer cells is added before transduction, so that the transduction efficiency of the virus vector can be remarkably improved. In particular, the present invention significantly improves the efficiency of a lentiviral vector having a low gene transfer efficiency in natural killer cells, and thus can be effectively used for preparing natural killer cells into which genes having desired properties are introduced, thereby maximizing the function, activity, and productivity of the cells with respect to immunotherapy.
Owner:GC CELL CORP

Nucleic acid molecules encoding modified retroviral gag proteins and uses thereof

PendingCN122278889AIncrease productionhigh titerInitiating MethionineRetrovirus
This invention discloses a nucleic acid molecule encoding a modified retroviral Gag protein and its applications. The Gag protein contains an engineered acylated tag sequence at its N-terminus, comprising: a glycine residue at the second position after the initiating methionine for myristylation modification; and / or a cysteine ​​residue in the N-terminal region for palmitoylation modification. The tag sequence is selected from SEQ ID NO:1, 3-9, or derivative amino acid sequences having at least 80% identity and retaining function. Preferably, the modification involves replacing the first 9 amino acids at the N-terminus of the wild-type HIV-1 Gag protein with the aforementioned tag to enhance membrane anchoring and improve viral packaging efficiency. This invention also provides packaging plasmids containing this molecule, host cells, packaging systems, and preparation methods. This invention can significantly improve viral yield and titer, and is particularly suitable for overcoming the efficiency bottleneck in packaging large-load lentiviruses of 7-10 kb.
Owner:TSINGHUA UNIVERSITY

A serum-free culture medium for γδT cells and its application

ActiveCN118703437Benhance cell viabilityIncrease multipleCulture processBlood/immune system cellsT cellCell kill
The present invention belongs to the field of biotechnology, and in particular to a serum-free medium for γδT cells and its application, wherein the medium includes a basal medium and an added complex, wherein the basal medium is any one of an X-Vivo15 medium or a KBM581 medium; the added complex includes: TWS119 with a final concentration of 0.5-5 μM / L, MnTBAP chloride with a final concentration of 1-10 μM / L, DL-α-tocopherol acetate with a final concentration of 0.5-2 mg / L, and zoledronic acid with a final concentration of 1-20 μM / L. The culture medium of the present invention cultivates γδT cells without the need for additional addition of serum or serum substitutes, can significantly improve the γδT cell expansion multiple, and can improve the transduction efficiency of CAR into γδT cells, while having good CAR-γδT cell killing tumor cell efficiency.
Owner:GENETIMES EXCELL TECH INC

Low-immunogenicity AAV gene therapy vector based on polynucleotide as well as preparation method and application of low-immunogenicity AAV gene therapy vector

The invention relates to the field of gene therapy, in particular to a low-immunogenicity AAV gene therapy vector based on polynucleotide and a preparation method and application thereof, and the vector comprises transgene for coding therapeutic protein, modified polynucleotide, low-immunogenicity AAV capsid protein and an immunoregulation module; the transgene is disposed between inverted terminal repetitions of the AAV; the low-immunogenicity AAV capsid protein is selected from a wild type of AAV5, AAV8 or AAV9 or a modified variant of the wild type of AAV5, AAV8 or AAV9; the immunoregulation module comprises a miRNA (micro Ribonucleic Acid) or shRNA ( Through polynucleotide modification and an immunoregulation module, the immunoreaction is reduced, and the stability and continuous expression ability of the AAV gene therapy vector in a host are improved; by selecting the AAV capsid protein, the transduction efficiency of the vector in a specific tissue is improved, so that the vector can reach a target tissue more effectively.
Owner:瑞吉明(山东)生物科技有限公司

Novel adeno-associated virus variant library for gene and cell therapy as well as construction and application of novel adeno-associated virus variant library

The invention discloses a novel adeno-associated virus variant library for gene and cell therapy as well as construction and application of the novel adeno-associated virus variant library, and belongs to the field of biological medicines. Through high-throughput sequencing and gene editing, an AAV variant library containing a large number of mutants is constructed, the construction efficiency is improved, the diversity of the mutants is ensured, the cap gene of AAV is modified by the variant library through a site-directed mutagenesis technology, the transduction efficiency of human immune cells is improved, the limitation of an existing AAV modification method is overcome, and the AAV mutant library has good application prospects. The constructed novel AAV variant library has higher packaging efficiency, lower cytotoxicity and better adaptability, and provides more choices for development of gene therapy drugs; the screened novel AAV6 variant P482L has remarkable advantages in the aspects of transduction efficiency, safety and the like, and becomes a potential candidate vector in the field of gene therapy; the invention not only accelerates the progress of new drug research and development, but also provides a new tool and method for treating hereditary diseases, tumors and the like, and promotes the development of the field of gene therapy.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Truncated transposase, transposome system and applications thereof

The application provides a truncated transposase, a transposon system and application thereof. Compared with a wild-type PS transposase, the truncated transposase lacks 1-50 amino acids at the C terminal of the wild-type PS transposase, preferably 44 amino acids. By deleting the amino acids at the C terminal of the transposase which have less influence on transposition, the length of the transposase is shortened, which is beneficial to the expression of the transposase and the preparation of a fusion protein, so that a transposase or a fusion protein thereof with higher catalytic activity and smaller size is obtained. The application also provides a fusion protein of the transposase, which is preferably fused with a leucine zipper through a linker, and a transposon system comprising the transposase and the transposon, which has great application value in the transgenic industry.
Owner:MAXIRNA (SHANGHAI) PHARM CO LTD +2

Preparation method of efficient AAV vector for gene therapy and AAV vector

The invention relates to the technical field of AAV vectors, in particular to a preparation method of an efficient AAV vector for gene therapy and an AVV vector, and the preparation method comprises the following steps: (1) creating a novel AAV capsid protein library through a DNA shuffling method; and (2) obtaining the AAV variant with high transduction efficiency through directed evolution screening, wherein the method specifically comprises the following steps: a) constructing a screening vector system containing a reporter gene; b) performing multiple rounds of screening in the HEK293T cells; c) sorting by a flow cytometry to obtain an AAV variant with high transduction efficiency; (3) optimizing an AAV genome packaging sequence; and (4) carrying out virus packaging and purification on the obtained AAV vector, and recombining dominant sequences of different serotypes on a molecular level through a DNA shuffling method, so that the diversity and quality of a gene pool are remarkably improved.
Owner:GUANGZHOU RUIDI BIOTECHNOLOGY CO LTD

A method for preparing a wearable potentiometric ion sensor based on conductive polymer nanofiber membranes

The application relates to a method for preparing a wearable potential ion sensor based on a conductive polymer nanofiber membrane and belongs to the field of electrochemical sensing. The method mainly comprises the following steps: (1) conductive polymer monomer solution and initiator-crosslinking agent mixed solution are successively drop-coated on the surface of an electrode, the latter induces monomer assembly polymerization, a conductive polymer nanofiber membrane is obtained, and drying is performed; (2) an ion-selective membrane dispersion liquid is prepared according to a certain proportion and is dropwise added to the electrode, and film drying is performed; (3) after the prepared electrode is dried overnight in the dark, the electrode is placed in a prepared standard ion solution (to-be-measured ion) for pretreatment; and (4) the electrode is placed in ion solutions with different concentrations for testing, the relationship between ion concentration and voltage is obtained, a standard curve and a linear equation are obtained, and monitoring of ion concentration in sweat is realized. The wearable potential ion sensor prepared by the method can realize high-sensitivity real-time monitoring of ions in sweat.
Owner:BEIJING UNIV OF TECH

Method and kit for improving lentivirus transduction efficiency and transduction stability of TIL cells

The invention relates to a method and a kit for improving lentivirus transduction efficiency and transduction stability of TIL cells. The invention relates to the technical field of biology. Specifically, the invention provides a method and a kit for promoting the lentivirus transduction efficiency and the transduction stability of TIL cells, BX-795 is added in the lentivirus infection process, the transduction efficiency can be improved to 60% or above, the transduction stability can be remarkably improved, and the viability of the TIL cells is not obviously influenced. The method for improving the lentivirus transduction efficiency and transduction stability of the TIL cells can be applied to obtaining genetically engineered TIL cells and promoting development and application of TIL cell therapy.
Owner:SHANGHAI CHUANGINSAI BIOTECHNOLOGY CO LTD